Working… Menu

Rivaroxaban for Antiphospholipid Antibody Syndrome (RAPS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02116036
Recruitment Status : Completed
First Posted : April 16, 2014
Last Update Posted : October 18, 2017
Heart and Stroke Foundation of Canada
Hamilton Health Sciences Corporation
Jewish General Hospital
University of Alberta
The Ottawa Hospital
Queen Elizabeth II Health Sciences Centre
Information provided by (Responsible Party):
St. Joseph's Healthcare Hamilton

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : September 30, 2017
Actual Study Completion Date : September 30, 2017